Acta neurologica Scandinavica
-
Acta Neurol. Scand. · Jan 2015
Observational StudyDrug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
The aim of the present observational study was to determine the effects of a delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) oromucosal spray (Sativex(®) spray), brand name Sativex(®), indicated for drug-resistant MS spasticity, on the driving ability of treated MS patients. ⋯ Treatment of MS patients with Sativex(®) does not negatively impact on driving ability and may improve moderate to severe treatment-resistant MS spasticity.